Small cell neuroendocrine tumour of the anterior tongue: A case report  by Cymerman, James A. et al.
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INTRODUCTION:  Neuroendocrine  carcinomas  (NECs)  are  rare  in the  oral  cavity.  There  is ambiguity
regarding  the classiﬁcation  of these  tumours,  but  their  aggressive  nature  is recognised  throughout  the  lit-
erature.  Merkel  cell carcinoma  (MCC)  is  rare and  more  frequent  in  skin,  though  it has  also  been  described
intra-orally.  High  grade  neuroendocrine  tumours  (HGNEC)  and  MCCs  behave  aggressively  and  aggressive
treatment  strategies  have  been  advocated.  We  describe  the  ﬁrst  small  cell  HGNEC  on the anterior  tongue.
PRESENTATION  OF  CASE:  We  present  the  ﬁrst  report  of a pT1pN1M0  small  cell  HGNEC  in a 75 year  old  man
on  the  left lateral  anterior  tongue.  This  was  widely  resected  with  20 mm  peripheral  and  deep  margins  to
achieve  disease  clearance.  Selective  neck  dissection  of  levels  1–4  was  also  carried  out.
DISCUSSION: Histological  analysis  of the  tumour  conﬁrmed  a primary  poorly  differentiated  neuroen-
docrine  tumour  of  small  cell  type  (small  cell  HGNEC).  Resected  node  bearing  tissue  from  levels  1–4
conﬁrmed  metastasis  to  a level  III node  with  no  extra  capsular  spread  giving  a  pT1pN1M0  classiﬁcation.
Margins  of 11.7  mm  from  the  invasive  tumour  to mucosal  margin  medially  and  7.0  mm  for  the deep  mar-
gin  despite  surgical  20 mm  margin  resection.  To  the  best  of our  knowledge  small  cell  neuroendocrine
carcinoma  has  not  been  described  in  the  anterior  tongue.
CONCLUSION: The  aggressive  nature  of  this  tumour  type  mandates  aggressive  surgical  resection  with
margins  similar  to those  now  recommended  for skin  Merkel  cell  carcinomas.  We advocate  a  wide  excision
margin  of  20  mm  to  give  adequate  clearance,  with  neck  dissection  in  order  to  pathologically  stage  this
cancer  type.
© 2013 Surgical Associates Ltd. Published by Elsevier Ltd. Open access under CC BY-NC-ND license. . Introduction
Neuroendocrine carcinomas (NECs) are rare in the oral cavity.
here is ambiguity regarding the classiﬁcation of these tumours,
ut their aggressive nature is recognised throughout the litera-
ure. Merkel cell carcinoma (MCC) is rare and more frequent in
kin, though it has also been described intra-orally. High grade neu-
oendocrine tumours (HGNEC) and MCCs behave aggressively and
ggressive treatment strategies have been advocated. We  describe
he ﬁrst small cell HGNEC on the anterior tongue.
. Presentation of caseA 75 year old gentleman presented to the Oral & Maxillofa-
ial Surgery department with a three month history of a painful,
on-healing ulcer on the left lateral border of his tongue. His
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Open access under CC BY-medical history was unremarkable. Initial examination showed a
5 mm  diameter ulcerated lesion on the left lateral border of his
tongue (Fig. 1). There was no clinical evidence of cervical lym-
phadenopathy and the remainder of his oral cavity examination
was normal.
A  diagnostic biopsy revealed features of a poorly differentiated
neuroendocrine carcinoma with a small cell component. Immuno-
histochemistry demonstrated the tumour cells to be strongly
positive for neuroendocrine markers (CD56, chromogranin and
synaptophysin) and epithelial markers (AE1/3, MNF116, CK7) and
focally strong CK20 positivity in the glandular component. Cells
were negative for melanoma and lymphoid markers.
Further investigations included MRI  neck, CT thorax, liver and
neck, blood proﬁling and an ECG. The primary lesion was  not
demonstrated on either of the scans.
Following discussion at the Head & Neck MDT meeting sur-
gical resection was  planned. The patient underwent temporary
tracheostomy, selective neck dissection (levels 1–4), excision of pri-
mary lesion (Fig. 2) with a radial forearm free ﬂap reconstruction
and full thickness abdominal skin graft to arm donor site. Surgery
proceeded without complication.
NC-ND license. 
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Fig. 1. Clinical photo showing tumour in-situ (centrally positioned).
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aFig. 2. Excised Tumour Specimen with 2 cm margins.
Histology macroscopically reported a nodular abnormality
pproximately 11 mm in maximum AP diameter. Microscopic
xamination of excised tissue (Figs. 3 and 4) showed tumour clear-
nce of 11.7 mm from the invasive tumour to mucosal margin
edially and 7.0 mm from deep margin. Analysis of 49 cervical
ymph nodes from levels 1–4 showed a single 7 mm metastasis
n level three in the left neck. There was no extracapsular spread.
ig. 3. Low-power view of poorly differentiated carcinoma with focal undifferenti-
ted  small cell like appearance (bottom right). H&E x 50.Fig. 4. High power view of undifferentiated small cell like morphology including
nuclear  debris. H&E X400.
Following head and neck cancer multidisciplinary MDT  review
adjuvant radiotherapy for the neck was  planned.
3. Discussion
In the head and neck mucosa, the majority of neuroendocrine
carcinomas (NECs) arise in the larynx, while the second most com-
mon  site is the salivary glands.1–3 NECs are rare in the oral cavity
with some confusion and ambiguity regarding the classiﬁcation
of these tumours. Merkel cell carcinoma (MCC) is another dis-
tinct neuroendocrine carcinoma reported most frequently on skin
and salivary glands, MCC  has been reported in the oral cavity. The
aggressive nature of these tumours is recognised throughout the
literature.3–5
The distinction among these different tumours in the head
and neck is important, and is usually accomplished using a
combination of clinical status, anatomic site, histology and
immunohistochemistry.4 The WHO  classiﬁcation of laryngeal NECs
is derived from that for lung NECs. This has been extrapolated to
other head and neck site primary mucosal NECs and comprises
tumour types listed in Table 1.
Surgery is the mainstay of treatment of NECs (including MCC)
at all body sites and has been reported to signiﬁcantly improve
survival overall over other single modality treatments.6–8 High
grade or poorly differentiated neuroendocrine tumours are aggres-
sive and to decrease local recurrence of these a wide excision
margin has been advocated (up to 3 cm)  though this can be
difﬁcult to accomplish in the head and neck.6–8 In this case a
Table 1
Classiﬁcation of neuroendocrine tumours (of the larynx) WHO  2005.
Terminology Synonyms
A. Typical carcinoid Carcinoid, well differentiated
(Grade  I) neuroendocrine
carcinoma
B.  Atypical carcinoid Malignant carcinoid, moderately
differentiated (Grade II)
neuroendocrine  carcinoma, large
cell neuroendocrine carcinoma
C.  Small cell carcinoma,
neuroendocrine type
Small cell neuroendocrine
carcinoma, poorly differentiated
(Grade  III) neuroendocrine
carcinoma
D.  Combined small cell carcinoma,
neuroendocrine type, with non-small
cell carcinoma (squamous cell
carcinoma, adenocarcinoma, etc.)
Combined small cell carcinoma,
composite  small cell carcinoma
E.  Paraganglioma Non-chromafﬁn paraganglioma
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7ig. 5. Immunohistochemistry indicating strong diffuse staininf for the neuroen-
ocrine  marker CD 56 including in the undifferentiated small cell like area.
D56  X50.
urgical margin of 20 mm resulted in microscopic clearance of only
1.7 mm at mucosal margin and 7 mm deep margin, reﬂecting
he inﬁltrative nature of this rare tumour type. Electrochemother-
py has also been described as effective therapy for Merkel cell
arcinoma in the head and neck and therefore may  have a role
ere.9
NECs demonstrate positive immunohistochemical staining for
ne or more neuroendocrine markers including: chromogranin A,
ynaptophysin, CD57, CD56, neuron-speciﬁc enolase, and neuroﬁl-
ment. Histological analysis of our tumour conﬁrmed a primary
oorly differentiated neuroendocrine tumour of small cell type
small cell HGNEC). This NEC was immunohistochemically pos-
tive for CD56 (Fig. 5), chromogranin and synaptophysin and
pithelial markers (AE1/3, MNF116, CK7) and focally strong
K20.
. Conclusion
NECs occurring within the oral cavity are an exceptionally rare
ntity. The aggressive nature of this tumour type at other sites
equires an early and precise diagnosis and mandates aggressive
urgical resection. We  advocate a wide excision margin of 2 cm to
ive adequate clearance in those patients who are ﬁt for such sur-
ical procedures. Electrochemotherapy may  have a role in patients
ot ﬁt for major surgery.
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